The Medicines Company

October 24, 2018
RNAi Therapeutics Come of Age: Exploring the Peaks & Troughs of Alnylam's Thirty Year Journey to First Approval
Categories

RNAi Therapeutics Come of Age: Exploring the Peaks & Troughs of Alnylam’s Thirty Year Journey to First Approval

[vc_row][vc_column][vc_column_text]   In August 2018, the FDA & European Commission announced the approval of Alnylam Pharmaceutical’s ONPATTRO, a first-of-its-kind RNA interference (RNAi) therapeutic. Evolution Executive’s latest […]
Do you like it?
Read more